As of beginning of March, Redoxis is now a registered trademark in the US. Redoxis has previously been a registered trademark in Sweden and European Union and was lately approved for registration by the United States Patent and Trademark Office.
“The registration of the trademark Redoxis in the US is an important step of our internationalisation strategy to increase Redoxis recognition within the American market for CRO services” says Peter Olofsson, founder and board member of Redoxis.
The current Covid-19 situation is clearly affecting all of us but Redoxis CRO services are still fully operational. In addition to our already validated and standardized animal models we routinely implement and set up new models on demand. With a fully equipped lab, we can also set up in vitro assays on demand, including flow cytometry, ELISA, Luminex and qPCR.
Contact us for a discussion on who we can facilitate and assist your preclinical development in inflammation and autoimmunity.
Successful translation of in vitro results to in vivo proof of concept data is essential in early drug development. Traditionally, in vitro models have had major limitations in predictability but the use of 3D cell cultures, mimicking structures in which cells resides in vivo, increased translatability can be achieved. We are now, in collaboration with Cellevate, looking for a student interested to take on a master project where new 3D ex vivo models for skin inflammatory diseases will be validated and evaluated for use in early drug discovery. The project will involve both practical lab work as well as in-depth theory and engineering of 3D nanofiber networks.
Alex Moreno joined our company fall of 2018 as an early stage researcher through the European Training Network COSMIC, funded from the European Union´s Horizon 2020 research and innovation program (NO 765158). Since then he has been focusing his research on B cell development and antibody mediated effects in arthritis models with very promising results. We are now happy to have him starting his doctoral education as an industrial PhD student at Redoxis, under supervision of Prof. Rikard Holmdahl at Karolinska Institute, Stockholm. During the next four years Alex will continue his work on evaluating the effect of antibodies in various models of autoimmune arthritis as well as characterise the B cell response in those models in a close collaboration between Redoxis and the research group at KI. .
In the end of December, Redoxis moved into new lab facilities within Medicon Village. With increased lab space and more offices, the new facilities allows us to continue our expansion and supports our aim to grow further within the next few years. An additional benefit from moving is that we are now closely situated to other CRO companies with complementing services, facilitating cross-company discussions and collaborations. Last week, we invited our new neighbours to an inauguration party to celebrate the we are now up and running in our new lab in building 403.